Researchers examine emerging data demonstrating that functionally distinct arrhythmia classes are associated with radiotherapy dose to discrete cardiac substructures. These observations may help guide potential mitigation efforts for lung cancer patients undergoing radiotherapy.
Presenter Dr. Alex Brunelli says neoadjuvant chemoimmunotherapy is a promising and well-tolerated treatment option in select patients with stage III NSCLC.
Can radiotherapy replace surgery in stage III NSCLC in the era of immunotherapy? During ELCC 23, Dr. Sara Ramella turned to the data to answer that question.
Advocacy group says its annual research events are key to its mission: Making EGFR-mutated lung cancer a manageable chronic disease.
Health Canada gives greenlight to cemiplimab-chemo combo for first-line treatment of advanced NSCLC. Early registration for WCLC 23 ends June 9.
During a recent interview with ILCN, Prof. Swanton reviewed the possible mechanisms at play when particulate matter triggers cancer growth and discussed new data that sheds additional light on the process.
Advocate Terri Ann DiJulio knows the stigma associated with smoking must end if more lung cancer patients are to be diagnosed and treated early. The first step is talking about it.
Spain’s Dr. Pilar Garrido reviews long-term efficacy, safety, and predictors-of-response data for post-platinum advanced NSCLC patients with EGFR exon 20 insertion mutations.
Dr. Christine Berg says both smoking and air pollution are important in causing lung cancer. And both need to be eliminated to help prevent it and save lives.
A team of NCI researchers recently investigated what needs to happen for the United States to reach President Biden’s goal of cutting cancer mortality by 50% by 2047.